Dados B3 › TELB4 × OIBR3
TELB4 × OIBR3
Indicators
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | TELB4 | OIBR3 | year |
|---|---|---|---|
| ROE | -8.5%! | -243.5% | 2021 |
| ROIC | -4.2%! | -91.3%! | 2022 |
| ROA | 3.3% | -212.9% | 2025 |
| Gross margin | -35.0% | -52.3% | 2025 |
| EBIT margin | 48.2% | -176.4%! | 2025 |
| Net margin | 28.6% | -1,399.8% | 2025 |
| Net debt/EBITDA | -4.73x | 11.73x | 2021 |
| Current ratio | 6.29x | 1.12x | 2025 |
| Revenue growth (1y) | 18.5% | -18.3% | 2025 |
| Revenue growth (5y CAGR) | 13.0% | -25.0% | 2025 |
| Piotroski F-Score | 6/9 | 4/9 | 2025 |
Point-in-time multiples
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | TELB4 | OIBR3 | year |
|---|---|---|---|
| P/E | 6.53x | 0.00x | 2025 × 2024 |
| P/B | 0.52x | — | 2025 × 2024 |
| EV/EBITDA | -1.14x | — | 2025 × 2024 |
| FCF yield | 2.9% | -352,559.1% | 2025 × 2024 |
Numbers on this page are live. Data version 2026-10-18-pl-classe-versoes · page generated 2026-10-23 16:09 UTC. If this does not match /saude, you are reading a cached copy.
Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.
Numbers on this page are live. Data version 2026-10-18-pl-classe-versoes · page generated 2026-10-23 16:09 UTC. If this does not match /saude, you are reading a cached copy.